Jiangsu Alphamab Biopharmaceuticals Co., Ltd.
- Biotech or pharma, therapeutic R&D
AlphaMab Oncology is a leading HKEX-listed biotechnology company committed to the research and development of innovative biopharmaceuticals for cancer treatment. The company currently has one product on the market, seven in various stages of clinical development and more in pre-clinical stage.
AlphaMab has established cutting-edge platforms for ADC development, such as the glycan-specific conjugation platform, proprietary linker-payload platform, and dual-payload platform, which enable the generation of globally competitive ADC assets with enhanced efficacy and safety profiles.
Alphamab is actively looking for partnership opportunities for its innovative bi-specific antibodies and ADC programs and proprietary glycan-specific dual-payload platform.
)
)
)
)
){kind=logo}
){kind=logo}
)
){kind=logo}
)
){kind=logo}
){kind=logo}